

Lilly

1876

150

2026

YEARS OF MEDICINE

Safe Harbor Provision and Other Information

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; trade and economic conditions; and changes in laws and regulations, including healthcare reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated.

The company undertakes no duty to update forward-looking statements except as required by applicable law.

Entering **NEW ERA** in treating people with obesity and related complications

FROM

TO



Portfolio

Single marketed product

Broad portfolio of medicines across expanded indications



Supply

Demand outpacing supply

Globally launched and widely available, with 13 sites under construction



Access

Coverage and payer *barriers*

Increasing government and employer coverage, new alternative access models



Direct patient engagement

Conventional pharma model

Innovative consumer mindset including LillyDirect platform

Expanding focus to help even more patients

BROAD PIPELINE

Launch & Late Phase Programs

TIRZEPATIDE

ORFORGLIPRON

ELORALINTIDE

RETATRUTIDE

BRENIPATIDE

6 Additional Clinical Stage Programs

34 Discovery Programs
INCRETINS | AMYLINS | NOVEL TARGETS

POTENTIAL TO HELP 1B PEOPLE



Obesity



Diabetes



Obstructive
Sleep Apnea



Pain



Cardiovascular



Renal



Hepatic



Others

Studying Incretins in New Diseases



Neuroscience



Inflammation

Investing \$55B to create sustainable advantage

13 sites under construction globally, with additional site forthcoming



Lebanon, Indiana (1)



Lebanon, Indiana (2)



Huntsville, Alabama



Carolina, Puerto Rico



Houston, Texas



Research Triangle Park, North Carolina



Concord, North Carolina



Indianapolis, Indiana



Katwijk, Netherlands



Limerick, Ireland



Goochland County, Virginia



Kenosha County, Wisconsin



Alzey, Germany

API and Dry Network

Parenteral and Devices Network



Advancing science across all therapeutic areas

NEW MEDICINES TO DRIVE FUTURE GROWTH

Launch & Late Phase Programs

IMLUNESTRANT

OLOMORASIB

PIRTOBRUTINIB

TERSOLISIB
(PI3K α)

SOFETABART
MIPITECAN (FR α)

VEPUGRATINIB

LEPODISIRAN

MUVALAPLIN

DONANEMAB

REMTERNETUG

LEBRIKIZUMAB

75%+ New clinical medicines are outside of incretins and amylin

PURSuing DISEASES WITH SIGNIFICANT UNMET NEEDS

Patients¹



Elevated lipoprotein(a)

63M



Chronic Pain

51M



Early Alzheimer's Disease

20M



Early Breast Cancer

3M

Speeding innovation to patients

DIFFERENTIATED DEVELOPMENT ENGINE

3.5 years faster

vs industry from discovery to first launch¹

24 NME launches

from 2015-2025

NEW PLATFORMS TO ADDRESS UNMET NEED



Antibody Drug Conjugates



Radioligand Therapies



siRNA



Genetic Medicine

ACQUIRING PROMISING SCIENCE

39 transactions

in 2025 including:



\$4 billion+

capital deployed in 2025

Innovating beyond the molecule



Supported **180+ biotech companies** since 2023



Collaboration with **NVIDIA**
Building industry's **most powerful supercomputer**



Served **1 million+** patients in 2025

Trademarks

All trademarks and trade names referred to in this presentation are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this presentation, the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.